These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20477438)

  • 21. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.
    Mian C; Lodde M; Comploj E; Palermo S; Mian M; Maier K; Pycha A
    Anticancer Res; 2005; 25(5):3641-4. PubMed ID: 16101194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular markers for transitional cell carcinoma of bladder].
    Kleinmann J; Siegel YI; Zisman A
    Harefuah; 2003 Jul; 142(7):531-5, 565. PubMed ID: 12908389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.
    Lotan Y; Shariat SF; Schmitz-Dräger BJ; Sanchez-Carbayo M; Jankevicius F; Racioppi M; Minner SJ; Stöhr B; Bassi PF; Grossman HB
    Urol Oncol; 2010; 28(4):441-8. PubMed ID: 20610281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urothelial cancer biomarkers for detection and surveillance.
    Liou LS
    Urology; 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4. PubMed ID: 16530072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
    Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
    Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A side by side comparison of cytology and biomarkers for bladder cancer detection.
    Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V
    J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.
    Mian C; Maier K; Comploj E; Lodde M; Berner L; Lusuardi L; Palermo S; Vittadello F; Pycha A
    Cancer; 2006 Feb; 108(1):60-5. PubMed ID: 16411183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current bladder cancer tests: unnecessary or beneficial?
    Simon MA; Lokeshwar VB; Soloway MS
    Crit Rev Oncol Hematol; 2003 Aug; 47(2):91-107. PubMed ID: 12900004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
    Lokeshwar VB; Soloway MS
    J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor marker tests in bladder cancer].
    Feil G; Stenzl A
    Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multiprobe FISH for enhanced prediction of recurrent bladder cancer].
    Zellweger T; Benz G; Herzog M; Grilli B; Mihatsch MJ; Gasser TC; Bubendorf L
    Verh Dtsch Ges Pathol; 2004; 88():194-8. PubMed ID: 16892552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
    Toma MI; Friedrich MG; Hautmann SH; Jäkel KT; Erbersdobler A; Hellstern A; Huland H
    World J Urol; 2004 Jun; 22(2):145-9. PubMed ID: 14991320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical evaluation of urinary markers for bladder cancer detection and monitoring.
    Shariat SF; Karam JA; Lotan Y; Karakiewizc PI
    Rev Urol; 2008; 10(2):120-35. PubMed ID: 18660854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for detection and surveillance of bladder cancer.
    Budman LI; Kassouf W; Steinberg JR
    Can Urol Assoc J; 2008 Jun; 2(3):212-21. PubMed ID: 18682775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological possibilities and pitfalls in detecting aggressive bladder cancer.
    Mitra AP; Jordà M; Cote RJ
    Curr Opin Urol; 2012 Sep; 22(5):397-404. PubMed ID: 22825461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma.
    Gong YW; Wang YR; Fan GR; Niu Q; Zhao YL; Wang H; Svatek R; Rodriguez R; Wang ZP
    Transl Cancer Res; 2021 Jul; 10(7):3192-3205. PubMed ID: 35116626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study.
    Horstmann M; Banek S; Gakis G; Todenhöfer T; Aufderklamm S; Hennenlotter J; Stenzl A; Schwentner C;
    Springerplus; 2014; 3():24. PubMed ID: 24478941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.